EKR Therapeutics, Inc. (EKR Therapeutics) is a privately held company engaged in the development and commercialization of critical care products for acute care hospital setting. The product portfolio of the company consists of cardene IV, depodur, gelclair and retavase. Cardene IV is used for the short-term treatment of hypertension, depodur is an extended-release liposome injection of morphine sulfate for the treatment of pain, gelclair is a bio-adherent oral gel for the management of pain and relief of pain and retavase is used for acute myocardial infarction (AMI) in adults to improve ventricular function. The company is headquartered at Bedminster in New Jersey, the US.